Combimatrix Corp (CBMX) 2.97 $CBMX
CombiMatrix Launches Next Generation Sequencing for Pre-Implementation Genetic Screening
GlobeNewswire - Wed Jun 01, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre-implantation genetic diagnostics and screening, miscarriage analysis, prenatal and pediatric diagnostics, announces that it will begin accepting samples for pre-implantation genetic screening (PGS) by next generation sequencing (NGS) in mid-June.
CBMX: 2.97 (-0.13)
CombiMatrix to Present at Upcoming Investment Conferences
GlobeNewswire - Wed May 25, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre-implantation genetic diagnostics and screening, miscarriage analysis, prenatal and pediatric diagnostics, announces that that management will present at two upcoming investment conferences:
CBMX: 2.97 (-0.13)
CombiMatrix Comments on Additional Medical Policy Revisions to Reimburse for Recurrent Pregnancy Loss Testing
GlobeNewswire - Tue May 10, 5:44AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre-implantation genetic diagnostics and screening, miscarriage analysis, prenatal and pediatric diagnostics, noted that within the past two weeks the following managed care companies have revised their medical policies for genetic testing of fetal tissue as medically necessary for the evaluation of pregnancy loss in patients in specific cases. The revised medical policies state: "Genetic testing may be indicated (if desired by parents): In cases of pregnancy loss at 20 weeks of gestation or earlier when there is a maternal history of recurrent miscarriage (defined as a history of 2 or more failed pregnancies); or in all cases of pregnancy loss after 20 weeks of gestation."
CBMX: 2.97 (-0.13)
CombiMatrix Corporation Reports First Quarter 2016 Financial and Operating Results
GlobeNewswire - Wed May 04, 3:05PM CDT
Revenues Increase 28% to $3.0 Million on Record Reproductive Health
CBMX: 2.97 (-0.13)
CombiMatrix Corporation to Release 2016 First Quarter Financial Results on May 4, 2016
GlobeNewswire - Wed Apr 27, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX) announces that it will release financial results for the three months ended March 31, 2016 after market close on Wednesday, May 4, 2016. CombiMatrix management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss those results and answer questions.
CBMX: 2.97 (-0.13)
CombiMatrix Notes Two Additional Blue Cross Blue Shield Health Plans Revise Medical Policies to Reimburse for Recurrent Pregnancy Loss Testing
GlobeNewswire - Tue Apr 26, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre-implantation genetic diagnostics and screening, miscarriage analysis, prenatal and pediatric diagnostics, notes that Blue Cross Blue Shield of Arkansas and Blue Cross Blue Shield of Tennessee have revised their medical policies to include reimbursement for chromosomal microarray analysis of fetal tissue for the evaluation of recurrent pregnancy loss. These health plans now cover cases of pregnancy loss at 20 weeks of gestation or earlier; or when there is a maternal history of recurrent miscarriage (defined as a history of two or more failed pregnancies).
CBMX: 2.97 (-0.13)
CombiMatrix Provides Strategic Update
GlobeNewswire - Thu Apr 21, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, has begun to explore strategic options including a range of potential M&A and business development opportunities to enhance shareholder value. As part of this effort, CombiMatrix has engaged Torreya Capital, a division of the Financial West Investment Group, Inc. ("Torreya"
, to advise the Company and its Board of Directors in this effort.
CBMX: 2.97 (-0.13)
CombiMatrix Comments on Medical Policy Revisions by Cigna Health and Three BCBS Health Plans to Reimburse for Recurrent Pregnancy Loss Testing
GlobeNewswire - Tue Mar 29, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces that global health provider Cigna Health Services, Blue Cross Blue Shield of North Carolina, Premera Blue Cross Blue Shield and Life Wise of Oregon, an affiliate of Premera, have all revised their medical policies to include chromosomal microarray testing as medically necessary for the evaluation of recurrent pregnancy loss (i.e., two or more consecutive pregnancy losses). Since the beginning of 2016, six health plans have revised their medical policies to include coverage of recurrent pregnancy testing.
CBMX: 2.97 (-0.13)
CombiMatrix Closes $8.0 Million Underwritten Public Offering
GlobeNewswire - Thu Mar 24, 8:59AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, today announced that it has closed its previously announced firm commitment underwritten public offering of 8,000 units of Series F convertible preferred stock and warrants at a price to the public of $1,000 per unit for gross proceeds of $8.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.
CBMX: 2.97 (-0.13), LTS: 2.43 (-0.07)
ACOG and SMFM Update Practice Bulletins Recommending Prenatal Genetic Assessment for All Pregnant Women Regardless of Age or Other Risk Factors
GlobeNewswire - Wed Mar 23, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces that the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) recently updated their practice bulletins recommending that all pregnant women regardless of age or other risk factors be offered prenatal assessment for aneuploidy and other genetic disorders. The updated information for prenatal testing was issued in Practice Bulletins "Prenatal Diagnostic Testing for Genetic Disorders" (Number 162, May 2016) and "Screening or Fetal Aneuploidy (Number 163, May 2016).
CBMX: 2.97 (-0.13)
CombiMatrix Prices $8.0 Million Underwritten Public Offering
GlobeNewswire - Mon Mar 21, 7:12AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, today announced that it has priced a firm commitment underwritten public offering of 8,000 units of Series F convertible preferred stock and warrants at a price to the public of $1,000 per unit for gross proceeds of $8.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.
CBMX: 2.97 (-0.13), LTS: 2.43 (-0.07)
CombiMatrix to Present at the ROTH Conference
GlobeNewswire - Wed Mar 09, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces that President and Chief Executive Officer Mark McDonough will present a company overview at the 28 Annual ROTH Conference on Wednesday, March 16, 2016, at 10:00 a.m. Pacific time (1:00 p.m. Eastern time). The conference is being held at The Ritz-Carlton, Laguna Niguel in Dana Point, Calif.
CBMX: 2.97 (-0.13)
CombiMatrix Migrates Miscarriage Analysis Microarray Testing to Newer Scanning Panel
GlobeNewswire - Tue Feb 09, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces the migration of its microarray-based miscarriage testing to the Illumina HumanCytoSNP-12 BeadChip array platform. CombiMatrix had previously performed miscarriage analysis on the Illumina CytoSNP-850K BeadChip microarray platform.
CBMX: 2.97 (-0.13)
CombiMatrix Study Published in Genetics in Medicine
GlobeNewswire - Mon Feb 01, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces the publication of data from a CombiMatrix study supporting the value of follow-up diagnostic testing to either confirm or rule out positive results for common chromosomal aneuploidies and microdeletion syndromes detected by non-invasive prenatal testing (NIPT).
CBMX: 2.97 (-0.13)
CombiMatrix Announces Commercial Launch of Microarray Testing for Stillbirth Analysis
GlobeNewswire - Thu Jan 28, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis and postnatal developmental disorders and pre-implantation genetic screening (PGS) services, announces the commercial launch of its SNP microarray genetic diagnostic testing for intrauterine fetal demise (IUFD), commonly known as stillbirth genetic testing.
CBMX: 2.97 (-0.13)
CombiMatrix Announces 1-for-15 Reverse Split of Common Stock
GlobeNewswire - Wed Jan 27, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis and postnatal developmental disorders and pre-implantation genetic screening (PGS) services, today announced stockholder approval of a reverse split of CombiMatrix Common Stock at a special meeting of stockholders.
CBMX: 2.97 (-0.13)
New Data From Multi-Year Study of Pregnancy Loss Support Efficacy and Diagnostic Power of CombiMatrix's Chromosomal Microarray Analysis
GlobeNewswire - Wed Jan 06, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis and postnatal developmental disorders and pre-implantation genetic screening (PGS) services, announces that new data from a multi-year study support the efficacy of SNP-based chromosomal microarray analysis (CMA) in detecting chromosomal imbalances. Data from the study conducted by CombiMatrix will be presented by Trilochan Sahoo, M.D., FACMG, the company's Vice President of Clinical Affairs and Director of Cytogenetics, at the World Congress on Recurrent Pregnancy Loss in Cannes, France on January 16, 2016.
CBMX: 2.97 (-0.13)
CombiMatrix Announces Multicycle Offering for Pre-Implantation Genetic Screening and Improved Cost Efficiencies
GlobeNewswire - Wed Dec 16, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis, postnatal developmental disorders, and pre-implantation genetic screening (PGS) services, today announced that it has launched its PGS Multicycle Program. The PGS Multicycle Program provides patients the flexibility of testing eight embryos over the course of 12 months for a one-time payment. CombiMatrix is the pioneer in per-embryo pricing in conjunction with PGS testing. With the addition of a multicycle PGS option, CombiMatrix continues to offer the most flexible, cost-effective solutions for patients while increasing the upfront cash payments received for genetic testing services.
CBMX: 2.97 (-0.13)
CombiMatrix Highlights Two Recent Developments
GlobeNewswire - Fri Dec 11, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis and postnatal developmental disorders and pre-implantation genetic screening (PGS) services, today highlighted two recent developments.
CBMX: 2.97 (-0.13)
CombiMatrix's Array for Pre-Implantation Genetic Screening Granted Conditional Approval From New York State Department of Health
GlobeNewswire - Thu Dec 10, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis and postnatal developmental disorders and pre-implantation genetic screening (PGS) services, today announced that its CombiPGS(TM) test for women undergoing in vitro fertilization (IVF) has received conditional approval from the New York State Department of Health. CombiPGS allows couples to screen embryo biopsy cells for chromosomal abnormalities prior to implantation of the embryo in order to maximize the chance of successful implantation and pregnancy progression and to decrease the likelihood of a miscarriage.
CBMX: 2.97 (-0.13)
CombiMatrix Launches Next Generation Sequencing for Pre-Implementation Genetic Screening
GlobeNewswire - Wed Jun 01, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre-implantation genetic diagnostics and screening, miscarriage analysis, prenatal and pediatric diagnostics, announces that it will begin accepting samples for pre-implantation genetic screening (PGS) by next generation sequencing (NGS) in mid-June.
CBMX: 2.97 (-0.13)
CombiMatrix to Present at Upcoming Investment Conferences
GlobeNewswire - Wed May 25, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre-implantation genetic diagnostics and screening, miscarriage analysis, prenatal and pediatric diagnostics, announces that that management will present at two upcoming investment conferences:
CBMX: 2.97 (-0.13)
CombiMatrix Comments on Additional Medical Policy Revisions to Reimburse for Recurrent Pregnancy Loss Testing
GlobeNewswire - Tue May 10, 5:44AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre-implantation genetic diagnostics and screening, miscarriage analysis, prenatal and pediatric diagnostics, noted that within the past two weeks the following managed care companies have revised their medical policies for genetic testing of fetal tissue as medically necessary for the evaluation of pregnancy loss in patients in specific cases. The revised medical policies state: "Genetic testing may be indicated (if desired by parents): In cases of pregnancy loss at 20 weeks of gestation or earlier when there is a maternal history of recurrent miscarriage (defined as a history of 2 or more failed pregnancies); or in all cases of pregnancy loss after 20 weeks of gestation."
CBMX: 2.97 (-0.13)
CombiMatrix Corporation Reports First Quarter 2016 Financial and Operating Results
GlobeNewswire - Wed May 04, 3:05PM CDT
Revenues Increase 28% to $3.0 Million on Record Reproductive Health
CBMX: 2.97 (-0.13)
CombiMatrix Corporation to Release 2016 First Quarter Financial Results on May 4, 2016
GlobeNewswire - Wed Apr 27, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX) announces that it will release financial results for the three months ended March 31, 2016 after market close on Wednesday, May 4, 2016. CombiMatrix management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss those results and answer questions.
CBMX: 2.97 (-0.13)
CombiMatrix Notes Two Additional Blue Cross Blue Shield Health Plans Revise Medical Policies to Reimburse for Recurrent Pregnancy Loss Testing
GlobeNewswire - Tue Apr 26, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre-implantation genetic diagnostics and screening, miscarriage analysis, prenatal and pediatric diagnostics, notes that Blue Cross Blue Shield of Arkansas and Blue Cross Blue Shield of Tennessee have revised their medical policies to include reimbursement for chromosomal microarray analysis of fetal tissue for the evaluation of recurrent pregnancy loss. These health plans now cover cases of pregnancy loss at 20 weeks of gestation or earlier; or when there is a maternal history of recurrent miscarriage (defined as a history of two or more failed pregnancies).
CBMX: 2.97 (-0.13)
CombiMatrix Provides Strategic Update
GlobeNewswire - Thu Apr 21, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, has begun to explore strategic options including a range of potential M&A and business development opportunities to enhance shareholder value. As part of this effort, CombiMatrix has engaged Torreya Capital, a division of the Financial West Investment Group, Inc. ("Torreya"
, to advise the Company and its Board of Directors in this effort. CBMX: 2.97 (-0.13)
CombiMatrix Comments on Medical Policy Revisions by Cigna Health and Three BCBS Health Plans to Reimburse for Recurrent Pregnancy Loss Testing
GlobeNewswire - Tue Mar 29, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces that global health provider Cigna Health Services, Blue Cross Blue Shield of North Carolina, Premera Blue Cross Blue Shield and Life Wise of Oregon, an affiliate of Premera, have all revised their medical policies to include chromosomal microarray testing as medically necessary for the evaluation of recurrent pregnancy loss (i.e., two or more consecutive pregnancy losses). Since the beginning of 2016, six health plans have revised their medical policies to include coverage of recurrent pregnancy testing.
CBMX: 2.97 (-0.13)
CombiMatrix Closes $8.0 Million Underwritten Public Offering
GlobeNewswire - Thu Mar 24, 8:59AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, today announced that it has closed its previously announced firm commitment underwritten public offering of 8,000 units of Series F convertible preferred stock and warrants at a price to the public of $1,000 per unit for gross proceeds of $8.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.
CBMX: 2.97 (-0.13), LTS: 2.43 (-0.07)
ACOG and SMFM Update Practice Bulletins Recommending Prenatal Genetic Assessment for All Pregnant Women Regardless of Age or Other Risk Factors
GlobeNewswire - Wed Mar 23, 5:00AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces that the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) recently updated their practice bulletins recommending that all pregnant women regardless of age or other risk factors be offered prenatal assessment for aneuploidy and other genetic disorders. The updated information for prenatal testing was issued in Practice Bulletins "Prenatal Diagnostic Testing for Genetic Disorders" (Number 162, May 2016) and "Screening or Fetal Aneuploidy (Number 163, May 2016).
CBMX: 2.97 (-0.13)
CombiMatrix Prices $8.0 Million Underwritten Public Offering
GlobeNewswire - Mon Mar 21, 7:12AM CDT
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, today announced that it has priced a firm commitment underwritten public offering of 8,000 units of Series F convertible preferred stock and warrants at a price to the public of $1,000 per unit for gross proceeds of $8.0 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.
CBMX: 2.97 (-0.13), LTS: 2.43 (-0.07)
CombiMatrix to Present at the ROTH Conference
GlobeNewswire - Wed Mar 09, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces that President and Chief Executive Officer Mark McDonough will present a company overview at the 28 Annual ROTH Conference on Wednesday, March 16, 2016, at 10:00 a.m. Pacific time (1:00 p.m. Eastern time). The conference is being held at The Ritz-Carlton, Laguna Niguel in Dana Point, Calif.
CBMX: 2.97 (-0.13)
CombiMatrix Migrates Miscarriage Analysis Microarray Testing to Newer Scanning Panel
GlobeNewswire - Tue Feb 09, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces the migration of its microarray-based miscarriage testing to the Illumina HumanCytoSNP-12 BeadChip array platform. CombiMatrix had previously performed miscarriage analysis on the Illumina CytoSNP-850K BeadChip microarray platform.
CBMX: 2.97 (-0.13)
CombiMatrix Study Published in Genetics in Medicine
GlobeNewswire - Mon Feb 01, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces the publication of data from a CombiMatrix study supporting the value of follow-up diagnostic testing to either confirm or rule out positive results for common chromosomal aneuploidies and microdeletion syndromes detected by non-invasive prenatal testing (NIPT).
CBMX: 2.97 (-0.13)
CombiMatrix Announces Commercial Launch of Microarray Testing for Stillbirth Analysis
GlobeNewswire - Thu Jan 28, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis and postnatal developmental disorders and pre-implantation genetic screening (PGS) services, announces the commercial launch of its SNP microarray genetic diagnostic testing for intrauterine fetal demise (IUFD), commonly known as stillbirth genetic testing.
CBMX: 2.97 (-0.13)
CombiMatrix Announces 1-for-15 Reverse Split of Common Stock
GlobeNewswire - Wed Jan 27, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis and postnatal developmental disorders and pre-implantation genetic screening (PGS) services, today announced stockholder approval of a reverse split of CombiMatrix Common Stock at a special meeting of stockholders.
CBMX: 2.97 (-0.13)
New Data From Multi-Year Study of Pregnancy Loss Support Efficacy and Diagnostic Power of CombiMatrix's Chromosomal Microarray Analysis
GlobeNewswire - Wed Jan 06, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis and postnatal developmental disorders and pre-implantation genetic screening (PGS) services, announces that new data from a multi-year study support the efficacy of SNP-based chromosomal microarray analysis (CMA) in detecting chromosomal imbalances. Data from the study conducted by CombiMatrix will be presented by Trilochan Sahoo, M.D., FACMG, the company's Vice President of Clinical Affairs and Director of Cytogenetics, at the World Congress on Recurrent Pregnancy Loss in Cannes, France on January 16, 2016.
CBMX: 2.97 (-0.13)
CombiMatrix Announces Multicycle Offering for Pre-Implantation Genetic Screening and Improved Cost Efficiencies
GlobeNewswire - Wed Dec 16, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis, postnatal developmental disorders, and pre-implantation genetic screening (PGS) services, today announced that it has launched its PGS Multicycle Program. The PGS Multicycle Program provides patients the flexibility of testing eight embryos over the course of 12 months for a one-time payment. CombiMatrix is the pioneer in per-embryo pricing in conjunction with PGS testing. With the addition of a multicycle PGS option, CombiMatrix continues to offer the most flexible, cost-effective solutions for patients while increasing the upfront cash payments received for genetic testing services.
CBMX: 2.97 (-0.13)
CombiMatrix Highlights Two Recent Developments
GlobeNewswire - Fri Dec 11, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis and postnatal developmental disorders and pre-implantation genetic screening (PGS) services, today highlighted two recent developments.
CBMX: 2.97 (-0.13)
CombiMatrix's Array for Pre-Implantation Genetic Screening Granted Conditional Approval From New York State Department of Health
GlobeNewswire - Thu Dec 10, 5:00AM CST
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis and postnatal developmental disorders and pre-implantation genetic screening (PGS) services, today announced that its CombiPGS(TM) test for women undergoing in vitro fertilization (IVF) has received conditional approval from the New York State Department of Health. CombiPGS allows couples to screen embryo biopsy cells for chromosomal abnormalities prior to implantation of the embryo in order to maximize the chance of successful implantation and pregnancy progression and to decrease the likelihood of a miscarriage.
CBMX: 2.97 (-0.13)
